Lacerta Therapeutics Signs Gene Therapy Research Partnership With UCB

UF startup and UF Innovate | Sid Martin Biotech alum Lacerta Therapeutics, a clinical-stage gene therapy company, announced a new gene therapy research collaboration with UCB, a global biopharmaceutical company. The research collaboration and licensing agreement with UCB will focus on a central nervous system (CNS) disease with a high unmet need.

“At Lacerta, we have dedicated our careers to the development of AAV gene therapy platforms and it remains our mission to advance these platforms and develop novel therapeutics for patients with neurodegenerative disorders,” said Dr. Edgardo Rodrίguez-Lebrón, president and chairman of the board at Lacerta. “We are looking forward to entering a new era, working in partnership with UCB. Our hope is that our combined expertise will lead to significant advances in identifying treatments for orphan CNS diseases.”

Learn more about Lacerta Therapeutics Signs Gene Therapy Research Partnership With UCB.